Dermorphin vs Thymagen
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
DermorphinImmune Support
Thymagen- Summary
- Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
- Thymagen is a dipeptide bioregulator (Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the thymus gland. It supports T-lymphocyte maturation, thymic function, and immune system normalization. As the thymus involutes with age (thymic atrophy), immune competence declines. Thymagen is used to support immune restoration, particularly in aging, post-illness recovery, and immunodeficiency states.
- Half-Life
- Estimated 30-60 minutes (longer than endorphins due to D-Ala)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Subcutaneous (research), Intrathecal (research), Intranasal (research)
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- Not established for human use; research doses vary widely
- 10 mg per day
- Frequency
- Not established
- Daily for 10–30 days
- Key Benefits
- Potent analgesia superior to morphine on a per-weight basis
- May reduce perception of fatigue in high-intensity activity
- Longer-lasting than endogenous opioids due to D-amino acid substitution
- Research tool for mu-opioid receptor pharmacology
- Potential therapeutic application in refractory pain
- Supports thymic epithelial cell function and T-cell maturation
- May partially restore thymic output reduced by age-related atrophy
- Normalizes T-lymphocyte subpopulation balance
- Supports immune recovery after illness, surgery, or chemotherapy
- Anti-aging effects on thymic tissue
- Complementary to Thymosin Alpha-1 and Thymalin in immune protocols
- May improve vaccine responsiveness in older individuals
- Side Effects
- High addiction and dependence potential (mu-opioid agonism)
- Respiratory depression at high doses
- Nausea, vomiting, constipation
- Sedation and cognitive impairment
- +2 more
- Generally well tolerated
- Mild injection site reactions
- No significant immunological adverse events reported
- Stacks With
- —
- —